NC525
Acute Myeloid Leukemia (AML)
PreclinicalActive
Key Facts
About NextCure
NextCure is a clinical-stage biotech focused on discovering and developing first-in-class immunomedicines for cancer and immune-related diseases. Founded on pioneering Yale University research, the company employs its proprietary FIND platform to systematically identify novel immunosuppressive targets beyond the PD-1/CTLA-4 axis. Its strategy targets patient populations unresponsive to existing immunotherapies, with a pipeline led by candidates against Siglec-15 and LAIR-1. The company went public in 2019 and is navigating clinical development with a focus on novel biology.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |
| oNKord® (Inaleucel) | Glycostem | Phase 1/2a |